Psoralen-ultraviolet A endures as one of the most powerful treatments in dermatology: reinforcement of this ‘triple-product therapy’ by the 2016 British guidelines

British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015

(2016) T.C. Ling et al.   BRITISH JOURNAL OF DERMATOLOGY

Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening

(2015) N. Schweintzger et al.   BRITISH JOURNAL OF DERMATOLOGY

Phototherapy in the elderly

(2015) J. B. Powell et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

(2015) Denis Jullien et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo

(2015) Jonathan M. Eby et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phototherapy in dermatology: A call for action

(2015) Henry W. Lim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

(2015) A. Nast et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bath-PUVA Therapy Decreases Infiltrating CCR4-Expressing Tumor Cells and Regulatory T Cells in Patients With Mycosis Fungoides

(2013) Hiroshi Kato et al.   Clinical Lymphoma Myeloma & Leukemia

Photo(chemo)therapy Reduces Circulating Th17 Cells and Restores Circulating Regulatory T Cells in Psoriasis

(2013) Takuya Furuhashi et al.   PLoS One

Cytochrome P450 CYP1B1 Interacts with 8-Methoxypsoralen (8-MOP) and Influences Psoralen-Ultraviolet A (PUVA) Sensitivity

(2013) Yusuf Y. Deeni et al.   PLoS One

Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00

(2012) S. Whittaker et al.   BRITISH JOURNAL OF DERMATOLOGY

The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: A 30-year prospective study

(2012) Robert S. Stern   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry

(2011) M. Inzinger et al.   BRITISH JOURNAL OF DERMATOLOGY

Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients

(2011) Joy Wan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy

(2010) S. Coimbra et al.   BRITISH JOURNAL OF DERMATOLOGY

8-Methoxypsoralen Plus Ultraviolet A Therapy Acts via Inhibition of the IL-23/Th17 Axis and Induction of Foxp3+ Regulatory T Cells Involving CTLA4 Signaling in a Psoriasis-Like Skin Disorder

(2010) T. P. Singh et al.   JOURNAL OF IMMUNOLOGY

Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks

(2009) S. Priya Sivanesan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY